Kura Oncology’s (KURA) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research note published on Monday morning, Benzinga reports. They currently have a $32.00 price target on the stock.

Several other research analysts have also recently issued reports on KURA. HC Wainwright reaffirmed a buy rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday. StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. Stifel Nicolaus decreased their price target on Kura Oncology from $28.00 to $26.00 and set a buy rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald restated an overweight rating on shares of Kura Oncology in a report on Friday, August 9th. Finally, Wedbush reiterated an outperform rating and issued a $37.00 target price on shares of Kura Oncology in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of Moderate Buy and a consensus target price of $30.50.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $19.04 on Monday. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.45 billion, a PE ratio of -8.77 and a beta of 0.88. The company’s 50-day moving average price is $20.60 and its two-hundred day moving average price is $20.69.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the firm posted ($0.53) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kura Oncology will post -2.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Signaturefd LLC lifted its position in Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Kura Oncology during the first quarter valued at $110,000. Saxon Interests Inc. purchased a new position in Kura Oncology in the first quarter valued at about $201,000. Entropy Technologies LP purchased a new position in Kura Oncology in the first quarter valued at about $218,000. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Kura Oncology during the 4th quarter worth about $176,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.